2017
Immuron's fatty liver disease candidate advancing — 4 insights
14 September 2017
Immuron is making progress on three clinical trials for IMM-124E, its nonalcoholic steatohepatitis and nonalcoholic fatty liver disease treatment. Here's what you should know.
In dash to NASH, Immuron targets the gut not the liver
28 March 2017
Cookies and milk or cookies and colostrum? Immuron is targeting inflammatory bacteria in the gut with an engineered colostrum formulation, designed to prevent the liver damage that leads to NASH.
Biotech tackles hospital infection
17 March 2017
